Lung cancer remains one of the world’s leading causes of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for more than 80% of all lung cancer cases. In 2020 alone, more than 2.2 million new lung cancer cases were diagnosed worldwide

As precision oncology continues to transform NSCLC management, EGFR mutation testing has become a cornerstone of precision medicine. Activating mutations in the epidermal growth factor receptor (EGFR) gene are among the most clinically actionable biomarkers in NSCLC, enabling the selection of targeted therapies that significantly improve clinical outcomes in eligible patients.

Compared with conventional chemotherapy, EGFR tyrosine kinase inhibitors (TKIs) selectively inhibit aberrant EGFR signaling pathways that drive tumor growth and progression, offering improved efficacy and a more favorable safety profile for patients with EGFR-mutated NSCLC. Accurate and timely identification of EGFR mutations is therefore essential for selecting the most appropriate first-line therapy and supporting subsequent treatment decisions as resistance evolves.

Guideline Highlights

Leading international clinical guidelines consistently emphasize the importance of comprehensive biomarker testing in patients with advanced NSCLC.

NCCN Clinical Practice Guidelines in Oncology

-Recommend comprehensive molecular testing before initiating first-line targeted therapy in patients with advanced or metastatic NSCLC.

-EGFR mutation status is essential for selecting appropriate targeted therapies.

ESMO Clinical Practice Guideline

Recommends routine testing for EGFR mutations in exons 18–21 to identify patients eligible for EGFR-targeted therapies.

These guideline recommendations highlight the critical role of accurate, sensitive, and timely EGFR mutation testing in enabling precision treatment for patients with NSCLC.

Human EGFR Gene 29 Mutations Detection Kit (Fluorescence PCR)-Precision Detection for Confident Treatment Decisions

Macro & Micro-Test’s Human EGFR Gene 29 Mutations Detection Kit (Fluorescence PCR) enables rapid and accurate detection of 29 clinically significant EGFR mutations across exons 18–21, supporting precision treatment decisions throughout the patient journey.

The assay detects both drug-sensitizing and resistance-associated mutations, helping clinicians identify patients who may benefit from EGFR-targeted therapies such as gefitinib and osimertinib, while supporting therapeutic decision-making throughout the course of treatment.

Why Choose Macro & Micro-Test’s EGFR Testing Kit?

Comprehensive Mutation Coverage

• · Detects 29 clinically relevant EGFR mutations across exons 18–21
• · Covers both drug-sensitizing and resistance-associated mutations
• · Improved ARMS Technology with patented enhancer for enhanced specificity
• · Enzymatic Enrichment reduces wild-type background and improves detection accuracy
• · Temperature Blocking Technology minimizes mismatched amplification and enhances specificity
• · Detects mutations with 1% mutant allele frequency
• · Objective results within 120 minutes
• · Internal control and UNG enzyme minimize false-positive results
• · Supports both tissue, plama or serum samples
• · Compatible with mainstream real-time PCR instruments
• · 12-month shelf life

Advanced Detection Technology

High Analytical Performance

Flexible Workflow

Guide Therapy with Confidence

Reliable EGFR mutation testing enables clinicians to make informed treatment decisions from initial diagnosis through resistance monitoring.

One assay. Comprehensive mutation coverage. Greater confidence in clinical decision-making.

Expand Your Precision Oncology Portfolio

Macro & Micro-Test also offers a comprehensive portfolio of molecular diagnostic solutions for precision oncology, including:KRAS, BRAF, ROS1, ALK, BCR-ABL, TEL-AML and more…

Explore our oncology solutions: marketing@mmtest.com